MolMed S.p.A. will present further data on the efficacy of its investigational drug NGR-hTNF in combination with doxorubicin in soft tissue sarcomas, tomorrow at the European Cancer Congress 2013 taking place in Amsterdam from September 27th to October 1st 2013.
